Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
$30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones Led by Vivo Capital with participation from RA Capital, BVF Partners, Logos Capital, and supported by existing investors Nantahala Capital Partners and Rosalind Advisors Inc. Vivo Capital's Gaurav Aggarwal, MD to join the Board Company to implement mandatory dividend policy upon achievement of profitability LOS ALTOS, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY) (the "Company" or "Unicycive"), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the Company has signed a securities p
